After all that effort with alpha-blockers, beta-blockers, ACE inhibitors, etc....are we just going to circle back to diuretics?? Will Eli Lilly fork over $1,000,000,000 to make Zyprexa marketing …
Cholesterol – good, bad, and indifferent
What a week it was for cholesterol! It was Lipidemia Rollercoaster - here's a summary. First, the kerfuffle with Vytorin. As you have probably heard, Merck and Schering-Plough have been roundly …
Continue Reading about Cholesterol – good, bad, and indifferent →